What Is MGF (Mechano Growth Factor) and PEG-MGF?

MGF (Mechano Growth Factor) is a splice variant of insulin-like growth factor 1 — specifically the IGF-1Ec isoform — that is expressed in mechanically loaded or damaged muscle and is studied as a local tissue-repair factor in muscle-research models. PEG-MGF is a pegylated form of the peptide, engineered to improve stability and extend half-life for use in research settings.

Research-use-only (RUO) note: this article is educational and describes preclinical, in-vitro, and animal findings only. The peptides discussed are not drugs, are not for human or veterinary use, and nothing here is a health, dosing, or treatment claim.

Quick facts

• Class: IGF-1 splice variant (IGF-1Ec) — a naturally occurring isoform produced by alternative splicing of the IGF-1 gene.
• PEG-MGF: a pegylated (PEG-conjugated) form of MGF, designed for greater stability in research handling.
• Research focus: muscle satellite-cell activation and local tissue-repair research, in cell culture and animal models.

What is MGF?

The IGF-1 gene does not produce a single protein. Through alternative splicing of its exons, it generates several isoforms, including IGF-1Ea and IGF-1Ec. The IGF-1Ec isoform — commonly called Mechano Growth Factor (MGF) — is notable because its expression rises in skeletal muscle in response to mechanical loading, stretch, and tissue damage in research models. MGF consists of the mature IGF-1 region plus a distinct C-terminal “E domain” peptide unique to this splice variant. In muscle research, MGF is described as a local factor produced within the tissue itself, rather than a systemic, circulating hormone.

MGF vs PEG-MGF

Native MGF is reported to be highly unstable, with a very short functional duration in solution and in circulation in research models. PEG-MGF addresses this by attaching a polyethylene glycol (PEG) molecule to the peptide — a process called pegylation. Pegylation is a well-established laboratory technique for increasing a peptide’s molecular size and resistance to degradation, which extends its half-life and prolongs the window over which researchers can study its activity. In short: MGF is the naturally occurring splice-variant peptide, and PEG-MGF is a modified version intended to be more durable for experimental work.

What does the research show?

In a foundational in-vitro study, Yang and Goldspink reported that the distinct E domain of MGF behaved differently from mature IGF-1: it increased myoblast (muscle-precursor cell) proliferation while inhibiting their terminal differentiation. Notably, blocking the IGF-1 receptor with a specific antibody did not abolish the MGF E-domain effect, suggesting its activity may be mediated through a different pathway in these cell models. Later cell-culture work by Kandalla and colleagues examined synthetic MGF E-peptide on primary human muscle progenitor (satellite) cells from donors of different ages, reporting increased proliferative lifespan and fusion potential in vitro, with the response varying by donor age. Separately, characterization work on IGF-1Ec/MGF within tissues has confirmed its status as an alternatively spliced IGF-1 variant.

Mechanisms studied in the lab

• Satellite-cell activation: the MGF E-peptide is studied for its apparent ability to activate quiescent satellite (muscle stem) cells and drive proliferation in vitro, an early step in muscle-repair models.
• Distinct C-terminal E peptide: the unique E domain — the part distinguishing MGF from other IGF-1 isoforms — is the focus of much mechanistic research, including evidence that some of its effects may not depend solely on the classical IGF-1 receptor.
• Proliferation vs. differentiation: research models position MGF as favoring precursor-cell proliferation, while mature IGF-1 is associated more with subsequent differentiation and fusion.

Research status

MGF and PEG-MGF are research compounds. The findings above come from in-vitro (cell-culture) and animal studies; they have not been established for any human use, and there are no approved human applications. These peptides are supplied strictly for laboratory research and analytical purposes — not for human or veterinary use, and not to diagnose, treat, cure, or prevent any condition.

Related research peptides

Bolt Peptide does not currently carry MGF or PEG-MGF. If you are researching the broader IGF-1 family, browse the full research peptide catalog, or read our overview of a related IGF-1 analog in What is IGF-1 LR3?

FAQ

Is PEG-MGF the same as MGF? No. PEG-MGF is MGF with a polyethylene glycol group attached. The pegylation is intended to improve stability and extend half-life in research settings; the underlying peptide sequence of interest is the same MGF (IGF-1Ec) splice variant.

Is MGF the same as IGF-1? Not exactly. MGF (IGF-1Ec) is one of several splice variants produced from the IGF-1 gene. It shares the mature IGF-1 region but carries a distinct C-terminal E-domain peptide that is the focus of separate research.

Can I use MGF or PEG-MGF? No. These are research-use-only compounds intended for qualified laboratory research only. They are not approved for human use, and this article provides no dosing or usage guidance.

References

1. Yang SY, Goldspink G. Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. FEBS Lett. 2002.
2. Kandalla PK, et al. Mechano Growth Factor E peptide (MGF-E) activates human muscle progenitor cells. Mech Ageing Dev. 2011.
3. Schlegel W, et al. IGF-1 Ec/Mechano Growth Factor — a splice variant of IGF-1 within the growth plate. PLoS One. 2013.

For research use only. Not for human or veterinary use; not FDA-approved. Statements have not been evaluated by the FDA.